Neuroprotection for stroke: current status and future perspectives.

Area of Science:

• Neurology
• Translational Medicine
• Neuroscience

Background:

• Neuroprotection aims to prevent neuronal death, showing promise in experimental stroke models.
• Clinical trials for neuroprotective agents have largely failed, despite preclinical efficacy.
• Key challenges include methodological discrepancies between preclinical and clinical studies and stroke patient heterogeneity.

Purpose of the Study:

• To analyze the reasons for the failure of neuroprotection translation in clinical stroke trials.
• To identify strategies for improving the success rate of neuroprotective treatments in stroke patients.
• To highlight current and future neuroprotective approaches and research directions.

Main Methods:

• Review of preclinical stroke research methodologies and clinical trial outcomes.
• Analysis of adherence to international guidelines like the Stroke Academic Industry Roundtable (STAIR) criteria.
• Examination of emerging neuroprotective strategies targeting ischemic stroke pathophysiology.

Main Results:

• Despite following STAIR criteria, agents like NXY-059 and hematopoietic growth factors showed limited clinical success.
• Ongoing clinical trials investigate hypothermia and ebselen.
• Preclinical studies show promise for NADPH oxidase and PSD-95 inhibitors.

Conclusions:

• Improving translation necessitates multicenter preclinical studies, enhanced animal models, and aligned methodologies.
• Future success depends on novel preclinical testing concepts and mechanistic insights into the ischemic cascade.
• A deeper understanding of stroke pathophysiology is crucial for developing effective neuroprotective therapies.